Table 3.

Summary of IGSF4 Promoter Methylation (by MSP Analysis of Whole Tumors) in Primary HL and NHL

Samples		IGSF4 methylated (no. of cases)
HL	Classic	27/40 (67.5%)
	LP	2/5 (40%)
PTLD		4/11 (36%)
BL		6/7 (86%)
DLBCL		10/12 (83%)
FL		7/7 (100%)
ALCL		1/3 (33%)
Mantle cell lymphoma		4/4 (100%)

LP, lymphocyte predominant HL; PTLD, post-transplant lymphoproliferative disease; BL, Burkitt lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; ALCL, anaplastic large cell (Ki-1⁺) lymphoma.